Health Care/Hospital
Nefecon Included in the Reimbursement Drug List of "Beijing Puhui Health Insurance Program" as a First-in-Disease Therapy for IgA Nephropathy
SHANGHAI, May 12, 2023 /PRNewswire/ -- An imported version of Nefecon (budesonide) delayed release capsule has been added to the 2023 New Reimbursement Drug List of Specialized Medicines of the "Beijing Puhui Health Insurance Program." Nefecon is a first-in-disease treatment for adults with prim...
2023-05-12 07:40
3854
The Esaote Group presents its latest solutions for cardiac imaging at the EACVI Congress in Barcelona (Spain)
BARCELONA, Spain, May 11, 2023 /PRNewswire/ -- Esaote, one of the world's leading manufacturers of medical diagnostic systems (specifically, ultrasound, dedicated MRI and Medical IT systems) took part in the Congress held by the European Association of Cardiovascular Imaging inBarcelona on May 10...
2023-05-11 21:27
3341
Results of Phase I Clinical Study of Qilu Pharma's PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology
JINAN, China, May 11, 2023 /PRNewswire/ -- On May 8, 2023, the authoritative oncology journal, Journal of Hematology & Oncology (JHO, 2022 impact factor of 23.168) published the results of the Phase I clinical study of Qilu Pharma's immunotherapy bifunctional antibody, QL1706 (Title: First-in-hum...
2023-05-11 20:55
2249
KT&G reports 2023 Q1 results, on track to become a 'global top-tier' company
* Q1 revenue of KRW 1.396 trillion, operating profit of KRW 316.5 billion * Continued robust growth in combustibles and Heat Not Burn, fundamentals intact * Overseas Heat Not Burn sales volume and operating profit up 64.3%, 127% YoY * Overseas subsidiaries sales volume and revenue up 60%, 4...
2023-05-11 19:45
3488
Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Assay
SAN DIEGO, May 11, 2023 /PRNewswire/ -- "Today we are pleased to announce that Invivoscribe's LeukoStrat® CDx FLT3 Mutation Assay has been approved by BSI ( Netherlands) and the EMA as a Class C CDx assay, meeting the stringent new IVDR (Regulation (EU) 2017/746) requirements. Invivoscribe is one ...
2023-05-11 18:00
2370
PFIZER CALLS FOR MORE AWARENESS OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) - A RARE, LIFE-THREATENING DISEASE
KUALA LUMPUR, Malaysia, May 11, 2023 /PRNewswire/ -- In an effort to encourage people to take care of their heart health, Pfizer Malaysia is calling for Malaysians to learn more about transthyretin amyloid cardiomyopathy (ATTR-CM), a rare, life-threatening disease. ATTR-CM is caused by unstable ...
2023-05-11 16:10
2706
CEAT Ambernath plant receives five-star grading in British Safety Council Audit
CEAT Specialty (division of CEAT Tyres) is proud to announce that it's Ambernath facility has received a Five Star rating in the Occupational Health and Safety Audit conducted by the British Safety Council MUMBAI, India, May 11, 2023 /PRNewswire/ -- The company's Ambernath plant underwent a comp...
2023-05-11 16:05
2606
Nippon Express Italia Obtains IATA CEIV Pharma Certification for Its Facility near Milan Malpensa Airport
TOKYO, May 11, 2023 /PRNewswire/ -- Nippon Express Italia S.p.A. (hereinafter "NX Italia"), a group company of NIPPON EXPRESS HOLDINGS, INC., has acquired IATA CEIV Pharma certification*, a quality certificate for pharmaceutical transport established by the International Air Transport Association...
2023-05-11 14:00
2368
SHL Medical and MoonLake Immunotherapeutics collaborate to develop sonelokimab autoinjector
ZUG, Switerland, May 11, 2023 /PRNewswire/ -- SHL Medical, a world-leading provider of advanced drug delivery solutions, announced that it has signed a collaboration agreement with MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inf...
2023-05-11 09:00
3208
Innovent Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint
ROCKVILLIE, Md. and SUZHOU, China, May 11, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2023-05-11 08:45
4414
Late-Breaking Turn Biotechnologies Presentation at ISID to Show Cell Reprogramming with ERA™ Technology Renews Skin
MOUNTAIN VIEW, Calif., May 10, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell reprogramming company developing novel mRNA medicines for untreatable, age-related conditions, has been invited to present data showing that its epigenetic reprogramming technology rejuvenates human skin. Turn Bio's...
2023-05-10 21:00
2359
Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma
* Marketing Authorization granted for Tibsovo® as the first and only approved IDH1 targeted therapyin Europe * IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma, difficult and hard-to-treat cancer PARIS, May 10, 2023 /PRNewswire/ -- Servier, a global pharmaceutical group...
2023-05-10 20:58
1839
Doceree forms an exclusive partnership with Hello Health Group to strengthen its global footprint; forays into 8 South East Asian markets
The partnership opens a first-of-its-kind service for Hello Health Group's
pharmaceutical clients,enabling them to target HCPs with precision and
efficiency
NEW DELHI, May 10, 2023 /PRNewswire/ -- Doceree
2023-05-10 11:00
2876
The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy
ROCKVILLIE, Md. and SUZHOU, China, May 10, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and ...
2023-05-10 08:00
3463
Gencurix announced Korean and Japanese cancer patients' 15-year follow-up prognostic test clinical results
SEOUL, South Korea, May 9, 2023 /PRNewswire/ -- Gencurix
2023-05-10 08:00
2383
Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting
FLORENCE, Italy and NEW YORK, May 9, 2023 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading Italian pharmaceutical and diagnostics company, and Stemline Therapeutics ("Stemline"), a wholly-owned subsidiary of the Menarini Group, announced today that they will present new data related to ...
2023-05-09 22:57
2728
Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses
* This Phase 2 trial is evaluating three vaccine candidates: COVID-Influenza Combination, stand-alone influenza and high-dose COVID * Preliminary topline immune responses for all three vaccine candidates were robust versus authorized comparators * For the stand-alone influenza vaccine candid...
2023-05-09 18:28
2592
Indonesia's National Hospital deploys AppSealing to Protect its Mobile Apps and Customers' PHI
SAN JOSE, Calif., May 9, 2023 /PRNewswire/ -- National Hospital Indonesia (NHI)
today announced that it has deployedAppSealing
2023-05-09 15:28
2183
3 in 5 people Have Side Job to Help Make Ends Meet - Herbalife Asia Pacific Survey
SINGAPORE, May 9, 2023 /PRNewswire/ -- Herbalife, a global health and wellness company and community, released the findings of its 2023 Asia Pacific Side Job Survey which showed that almost 3 in 5 (59%) respondents have a side job, and the top reason for doing so is to make ends meet (61%). Other...
2023-05-09 12:22
906
IND Application for Phase Ⅲ Registration Study of KN026 in Combination with Chemotherapy for the First-line Treatment of Breast Cancer Was Approved by CDE
SUZHOU, China, May 9, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. jointly announced that the IND application was approved in China for the pivotal trial of the anti-HER2 bispecific antibody KN026 combined with Docetaxel (albumin-binding), i...
2023-05-09 10:00
2413
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 321 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 319 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 303 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39
Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07Most Read
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
2024-05-15 12:00
7077
Traveloka strengthens sustainability pledge as world's first Platinum Sponsor of GSTC
2024-05-13 16:42
5952
Casio to Release G-SHOCK-Surfrider Foundation Collaboration
2024-05-15 09:00
5204
